IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-06-16
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability
of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination
with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive
AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with
MRD+ AML after frontline treatment.